⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10529090 | 0.85 | — | — | |
| SCHEMBL8620503 | 0.75 | ALDH1A1 (0.30) | — | |
| SCHEMBL4946247 | 0.73 | — | — | |
| SCHEMBL6238591 | 0.72 | — | — | |
| SCHEMBL10940023 | 0.71 | — | — | |
| SCHEMBL1296 | 0.71 | — | — | |
| SCHEMBL7240952 | 0.71 | — | — | |
| SCHEMBL1331944 | 0.71 | — | — | |
| SCHEMBL2047670 | 0.70 | — | — | |
| Hno SCHEMBL2810131 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 566 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303569-A1 | HETEROCYCLIC COMPOUNDS AS THERAPEUTIC AGENTS | ARISAN THERAPEUTICS INC. (US) | 2023-09-28 | — | — | US | claimed |
| EP-4249479-A1 | GLUCOSIDE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Beijing Increase Innovative Drug Co., Ltd. (CN) | 2023-09-27 | — | — | EP | claimed |
| US-11352328-B2 | Heterocyclic compounds for the treatment of arenavirus | ARISAN THERAPEUTICS INC. (US) | 2022-06-07 | — | — | US | claimed |
| WO-2022108849-A1 | HETEROCYCLIC COMPOUNDS AS THERAPEUTIC AGENTS | ARISAN THERAPEUTICS INC. (US) | 2022-05-27 | — | — | WO | claimed |
| CN-114539231-A | Glucoside derivative and preparation method and application thereof | 北京盈科瑞创新药物研究有限公司 | 2022-05-27 | — | — | CN | claimed |
| US-20190308938-A1 | Heterocyclic Compounds for the Treatment of Arenavirus | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-10-10 | — | — | US | claimed |
| WO-2018013430-A2 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION | ARISAN THERAPEUTICS INC. (US) | 2018-01-18 | — | — | WO | claimed |
| WO-2013175281-A1 | USE OF SUBSTITUTED 2-PHENYL-3H-QUINAZOLIN-4-ONES AND ANALOGS FOR INHIBITING BROMODOMAIN AND EXTRA TERMINAL DOMAIN (BET) PROTEINS | RVX THERAPEUTICS INC. (CA) | 2013-11-28 | — | — | WO | claimed |
| US-20130281399-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | RVX THERAPEUTICS INC. (CA) | 2013-10-24 | — | — | US | claimed |
| EP-2408454-A2 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2012-01-25 | — | — | EP | claimed |
| WO-2010106436-A2 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2010-09-23 | — | — | WO | claimed |
| US-20090042957-A1 | Substituted Oxyarenes | BAYER CROPSCIENCE AG (DE) | 2009-02-12 | — | — | US | claimed |
| EP-1831145-A1 | SUBSTITUTED OXYARENES | Bayer CropScience Aktiengesellschaft (DE) | 2007-09-12 | — | — | EP | claimed |
| WO-2006069685-A1 | SUBSTITUTED OXYARENES | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2006-07-06 | — | — | WO | claimed |
| US-6992044-B1 | Substituted phenyluracils | BAYER CROPSCIENCE AG (DE) | 2006-01-31 | — | — | US | claimed |
| WO-2002017912-A1 | ENDOTHELIN ANTAGONISTS | ABBOTT LABORATORIES (US) | 2002-03-07 | — | — | WO | claimed |
| US-6187504-B1 | PHOTOSENSITIVE BLEND CONTAINING A NAPHTHALENE SULFONIUM SULFONATE DERIVATIVE PHOTOACID GENERATOR, RESIN HAVING ALKALI INSOLUBLE GROUPS CLEAVABLE BY ACID, AN ALKALI SOLUBLE RESIN AND A SOLUBILITY CONTROL AGENT; POSITIVES, RESOLUTION | JSR CORPORATION (JP) | 2001-02-13 | — | — | US | claimed |
| WO-1997031534-A1 | USE OF N-PHOSPHONOMETHYLGLYCINE ESTERS IN AQUEOUS SOLUTION AS HERBICIDES, AND NEW N-PHOSPHONOMETHYLGLYCINE ESTERS | BAYER AKTIENGESELLSCHAFT (DE) | 1997-09-04 | — | — | WO | claimed |
| EP-4396173-A1 | HERBICIDAL MALONAMIDES CONTAINING A CONDENSED RING SYSTEM | BASF SE (DE) | 2024-07-10 | — | — | EP | disclosed |
| US-4165384-A | ADRENERGIC BLOCKING AGENTS, CARDIOVASCULAR DISORDERS | AKTIEBOLAGET HASSLE (SE) | 1979-08-21 | — | — | US | disclosed |